Related Experiment Video
Updated: Sep 20, 2025

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
The 4 T's of ITP: Tailoring Therapies to Treat Thrombocytopenia
1Boston University School of Medicine, Boston, Massachusetts.
Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by the destruction of platelets and megakaryocytes. Its management has changed significantly in recent years, and at JADPRO Live Virtual 2021, David Hughes, PharmD, BCOP, reviewed the background and pathophysiology of ITP and clinical practice guidelines with an emphasis on patient preference when selecting first and subsequent lines of therapies in the chronic ITP setting.
Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by the destruction of platelets and megakaryocytes. Its management has changed significantly in recent years, and at JADPRO Live Virtual 2021, David Hughes, PharmD, BCOP, reviewed the background and pathophysiology of ITP and clinical practice guidelines with an emphasis on patient preference when selecting first and subsequent lines of therapies in the chronic ITP setting.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Tumor Immunotherapy
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Peripheral Artery Disease III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins

